Takeda – QDENGA ® Dengue Vaccine Approved by European Commission

Returning guest, Dr. Derek Wallace, MBBS, Vice President and Global Dengue Program Head at Takeda discusses the dengue program and the European Commission (EC) approval of the company’s dengue vaccine, QDENGA ® (TAK-003), for the prevention of dengue disease caused by any serotype in individuals from four years of age in the European Union (EU).

Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, he leads the global program team in the development of Takeda’s dengue vaccine, QDENGA ® (TAK-003). Dr. Wallace joined Takeda in September 2013 as Global Program Medical Director.

Dr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, he held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Dr. Wallace served as clinical team leader for Sanofi’s dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women’s health.

Dr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.

Liked it? Take a second to support healthprofessionalradio on Patreon!
Become a patron at Patreon!


Leave a Reply

You must be logged in to post a comment.